Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of Moderate Buy by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) has been given an average recommendation of “Moderate Buy” by the twelve research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target […]

Related Keywords

,Piper Sandler ,Adeoyey Olukotun ,Sanfordc Bernstein ,Arrowhead Pharmaceuticals Stock ,Nasdaq ,Arrowhead Pharmaceuticals Inc ,Securities Exchange Commission ,Voya Investment Management ,Arrowhead Pharmaceuticals Company Profile ,News Ratings For Arrowhead Pharmaceuticals Daily ,Arrowhead Pharmaceuticals ,Analyst Recommendations For Arrowhead Pharmaceuticals ,Hedge Funds Weigh In On Arrowhead Pharmaceuticals ,Get Rating ,Marketbeat Ratings ,Director Douglas ,Exchange Commission ,Director Adeoye ,Ivy Capital Management ,Investment Management ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Ratings ,Consensus ,